• Explore /
  • Poster
  • / A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.

A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.

Abstract Video & Slides Poster

Authors

Charles Drake

Charles G. Drake

Department of Medicine and Division of Hematology/Oncology, Columbia University Medical Center, New York, NY

Charles G. Drake , Jingsong Zhang , Mark N. Stein , Yuanfang Xu , Frank A. Seebach , Israel Lowy , Kosalai Kal Mohan , Glenn Kroog , Elizabeth Miller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03972657

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS5592)

DOI

10.1200/JCO.2020.38.15_suppl.TPS5592

Abstract #

TPS5592

Poster Bd #

173

Abstract Disclosures

Similar Posters

First Author: Jingsong Zhang

First Author: Mark N. Stein

First Author: William Kevin Kelly

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.

A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.

First Author: Kyriakos P. Papadopoulos